ClinicalTrials.gg
CompletedNCT04031742Updated Aug 9, 2023

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

A Phase 2/3 interventional study of IBI306 and IBI306 in Homozygous Familial Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.

Enrollment
7th of 11
18 · median 20
Started
2019
with 2 others
Phase 2/3
2 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
1 of 12
Innovent Biologics (Suzhou) Co. Ltd.

Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 2/3, and was the 3rd registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.

Read the detailed description

This is a phase 2b/3 study to assess the efficacy and safety of IBI306 in subjects with homozygous familial hypercholesterolemia. Part 1 is an open-label, two-arm, multicenter pilot study to evaluate efficacy and safety of IBI306 in subjects with homozygous familial hypercholesterolemia. Part 2 is an open-label, single-arm, multicenter study to evaluate efficacy and safety of IBI306 in subjects with homozygous familial hypercholesterolemia.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 to ≤ 80 years of age
  2. Diagnosis of homozygous familial hypercholesterolemia
  3. LDL cholesterol ≥ 130 mg/dL (3.4mmol/L)
  4. Triglyceride ≤ 400 mg/dL (4.5 mmol/L)
  5. Bodyweight of ≥ 40 kg at screening

Exclusion criteria

Exclusion Criteria:

  1. History of liver transplant
  2. Uncontrolled hypertension
  3. Moderate to severe renal dysfunction
  4. Active liver disease or hepatic dysfunction
  5. Known sensitivity to any of the products to be administered during dosing
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Part 1: IBI306

    Participants receive open-label IBI306 150 mg subcutaneously Q2W or 450 mg Q4W for 12 weeks.

    Biological: IBI306

  • Experimental
    Part 2: IBI306

    Participants receive open-label 450 mg Q4W subcutaneously for 12 weeks.

    Biological: IBI306

Interventions

  • BiologicalIBI306

    Administered by subcutaneous injection

  • BiologicalIBI306

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Part 1: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C).

    Time frame: Baseline and Week 12

  2. Part 2: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and Week 12

Other outcomes

  1. Number of investigational product-related adverse events.

    Time frame: Baseline and Week 12

  2. Number of ADA and Nab.

    Time frame: Baseline and Week 12

07

Study locations

1 site
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2021, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2019
First posted
Jul 24, 2019
StartActual
Sep 29, 2019
Primary completionActual
Dec 30, 2021
CompletionActual
Dec 30, 2021
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04031742
Responsible party
Sponsor
First posted
Jul 24, 2019
Start date
Sep 29, 2019
Primary completion
Dec 30, 2021
Completion
Dec 30, 2021
Last update
Aug 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion